Artificial oxygen carriers: a current review.
Artificial oxygen carriers: a current review.
复制标题
人造氧载体：最新评论。
作者：
Thad Henkel;Mark Oleck
人工氧载体不是血液替代品。它们用于将氧气运送到组织，并且是基于血红蛋白或基于全氟化碳的。推动人工氧载体发展的是涉及血液供应的安全性和数量的问题。目前在美国没有人工氧载体被批准用于临床。Hemopure已被批准在南非使用。生产Hemopure和PolyHeme的公司都是基于血红蛋白的氧载体，已经在美国提交了生物许可申请。Hemopure的III期试验已经完成，而PolyHeme目前正在PolyHeme城市救护车试验中进行III期试验。北美目前还没有针对全氟化碳的试验。
Artificial oxygen carriers are not blood substitutes. They serve to carry oxygen to tissues and are either hemoglobin based or perfluorocarbon based. Driving the development of artificial oxygen carriers are concerns involving both the safety and quantity of the blood supply. No artificial oxygen carriers are currently approved for clinical use in the United States. Hemopure has been approved for use in South Africa. The companies producing Hemopure and PolyHeme, both of which are hemoglobin-based oxygen carriers, have filed a Biologic License Application in the United States. Phase III trials have been completed for Hemopure, while PolyHeme is currently undergoing phase III trials in the PolyHeme Urban Ambulance Trial. No North American trials are under way for perfluorocarbons.